CD8A and malignant glioma: Phase 1 study of cellular immunotherapy for recurrent/refractory malignant glioma using intratumoral infusions of GRm13Z40-2, an allogenic CD8+ cytolitic T-cell line genetically modified to express the IL13-zetakine and HyTK and to be resistant to glucocorticoids in combination with interleukin-2